Resumo:
LidERA
Estudo de Fase III, global, randomizado, aberto, multicêntrico, avaliando a eficácia e segurança do giredestrant adjuvante em comparação com a terapia endócrina de escolha do médico em participantes com receptor de estrogênio confirmado histologicamente de estágio I-III de médio e alto risco (Câncer de mama precoce positivo para ER) e receptor do fator de crescimento epidérmico humano 2 (HER2) negativo.
Patrocinador:
Roche
Resumo:
São Paulo / SP
Instituição: IDOR São Paulo
Informações: 11 94257-9076 (WhatsApp) / 11 2109-8804
E-mail: nucleodecaptacao@idor.org
Cookie | Duração | Descrição |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |